Logo for Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Investor Relations Material

Latest events

Logo for Actinium Pharmaceuticals Inc

Study Result

Actinium Pharmaceuticals
Logo for Actinium Pharmaceuticals

Q3 2024

14 Nov, 2024
Logo for Actinium Pharmaceuticals

Q2 2024

4 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Actinium Pharmaceuticals Inc

Access all reports
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted radiotherapies. These therapies are designed to deliver cancer-killing radiation to patients with high unmet medical needs, particularly in oncology and hematology. Actinium's lead product candidate, I-131 apamistamab (Iomab-B), is in a pivotal clinical trial targeting elderly patients with relapsed or refractory acute myeloid leukemia for bone marrow transplant conditioning. Actinium Pharmaceuticals Inc. is based in New York, New York, and its shares are listed on the NYSE.